BeiGene ends its Phase 3 lung cancer trial for ociperlimab after a futility analysis. No new safety concerns were found, and study results will be shared later.

Sino-American biotech BeiGene (HKEX: 06160) today revealed it intends to discontinue its clinical development program for ociperlimab (BGB-A1217), an anti-TIGIT antibody, as a potential treatment for ...

Trontinemab is currently being studied in the Phase Ib/IIa Brainshuttle AD study assessing the safety, tolerability, ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new data were presented at the AD/PD 2025 International Conference on Alzheimer's and Parkinson's Diseases in ...

Akamis Bio, a clinical-stage oncology company using a proprietary Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to deliver novel immunotherapeutic payloads to solid tumors, today announced ...

On track to announce primary endpoint result from ORIGIN 3 trial this quarter (2Q 2025)U.S. FDA BLA submission for accelerated approval planned ...

BeiGene is scrapping ociperlimab over a disappointing phase 3 outlook two years after Novartis handed back the anti-TIGIT ...

Gilead’s HIV franchise generated $19.612B in 2024, but faces future funding challenges. Learn why GILD stock is a "Hold" amid ...

ADRs came under pressure in the premarket on Thursday after the company announced its decision to halt a clinical program ...

Researchers have successfully developed a novel drug to restore vision. The treatment method restores vision through retinal nerve regeneration.

The FDA is expected to decide on treatments for COPD, psoriasis, rare neuroendocrine tumors, and a next-generation COVID-19 vaccine.